Celcuity to Present at the 2021 San Antonio Breast Cancer Symposium
12/02/2021 - 08:30 AM
MINNEAPOLIS, MN / ACCESSWIRE / December 2, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced that an abstract has been accepted for poster presentation at the 2021 San Antonio Breast Cancer Symposium (SABCS), which is being held virtually and in-person from December 7-10, 2021.
Poster presentation details are provided below.
Title: "Phase 1b expansion study of gedatolisib in combination with palbociclib and endocrine therapy in women with ER+ advanced breast cancer"Presenter: Rachel M. Layman, MDPoster Discussion: Spotlight Poster Discussion 13Poster Session: Poster Session 5 - Hall 1Presentation Time: December 10, 2021, 7 - 8:30 a.m. CT (8 - 9:30 a.m. ET)
The poster will be accessible on Celcuity's website at the same time.
For more details about SABCS please visit: https://www.sabcs.org/ .
About Celcuity
Celcuity is a clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic and companion diagnostic strategy. The company's therapeutic efforts are focused on developing molecularly targeted therapies that address the same cancer driver its companion diagnostics can identify. Its CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already approved targeted therapies. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com .
Contacts:
Celcuity Inc. Brian Sullivan, bsullivan@celcuity.com Vicky Hahne, vhahne@celcuity.com 763-392-0123
ICR Westwicke Robert Uhl, robert.uhl@westwicke.com 619-228-5886
SOURCE: Celcuity Inc.
View source version on accesswire.com: https://www.accesswire.com/675706/Celcuity-to-Present-at-the-2021-San-Antonio-Breast-Cancer-Symposium
CELC Rankings
#2062 Ranked by Stock Gains
CELC Stock Data
Industry
Medical Laboratories
Sector
Health Care and Social Assistance
Tags
Commercial Services, Miscellaneous Commercial Services, Health Care and Social Assistance, Medical Laboratories
About CELC
celcuity is a biotech company developing state-of-the-art cell-based assays using our proprietary functional cellular analysis platform. we directly assess the functionality of the disease-related signaling pathways of a patient's diseased cells ex vivo to determine whether a drug therapy has the intended effect on those cells. the patient specific cellular data we provide offers clinicians and pharmaceutical companies unique insight into a patient's response to a drug therapy, and it will change the paradigm of personalized medicine.